Ivabradina Krka (Ivabradine)

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, the natural pacemaker of the heart. This inhibition reduces the slope of spontaneous depolarisation, leading to a slower heart rate while preserving myocardial contractility and blood pressure, providing anti‑anginal and heart‑failure benefits.

The dose of Ivabradina Krka is individualized by the prescribing clinician based on the patient’s heart‑rate, clinical condition, and response to therapy. The prescriber determines the appropriate strength, frequency, and any necessary adjustments, following local prescribing guidelines.

Safety of ivabradine during pregnancy and lactation has not been established. It should be avoided unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Ivabradina Krka, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature requirements), and necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by directly inhibiting the If current without affecting myocardial contractility or blood pressure. Beta‑blockers act on adrenergic receptors and can reduce contractility and blood pressure. Ivabradine may be preferred when a pure heart‑rate reduction is needed without additional haemodynamic effects.

Store Ivabradina Krka at room temperature, below 25 °C, in the original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in bathrooms or near heat sources.

Ivabradina Krka is taken orally, usually with a glass of water. It can be taken with or without food, but consistency with respect to meals is recommended to maintain stable absorption. The tablet should be swallowed whole and not split or crushed unless specifically instructed by a pharmacist.

The most serious risks include symptomatic bradycardia that may require medical intervention, atrial fibrillation or other serious arrhythmias, and persistent visual disturbances such as retinal impairment. Patients should be monitored for these events, especially during dose initiation or when combined with other heart‑rate‑lowering agents.

Ivabradina Krka is contraindicated in patients with severe sinus bradycardia (resting heart rate <50 bpm), sick‑sinus syndrome, acute decompensated heart failure, uncontrolled hypotension, or those taking strong CYP3A4 inhibitors such as ketoconazole. It should also be avoided in individuals with known hypersensitivity to ivabradine or any excipients.